ERS International Congress, Madrid 2019

Browse by day: Saturday, 28.09.2019 Sunday, 29.09.2019 Monday, 30.09.2019 Tuesday, 01.10.2019 Wednesday, 02.10.2019		View the presentations you missed during Congress! More than 1,000 webcasts and slide presentations, 1,900 e-posters and 4,200 abstracts from the International Congress in Madrid and are now available.

Citations should be made in the following way: Authors. Title. Eur Respir J 2019; 54: Suppl. 63, abstract number.

Interstitial lung disease registries

Thematic Poster
Chairs: C. Valenzuela (Madrid, Spain), F. Hernandez Gonzalez (Barcelona, Spain), M. Vasakova (Praha 4, Czech Republic), V. Müller (Budapest, Hungary)

Download all media

Best tolerated dose of Pirfenidone in patients with idiopathic pulmonary fibrosis N. Agrawal (Vashi, Navi Mumbai, India), P. Vaidya (Vashi, Navi Mumbai, India), V. Chavhan (Vashi, Navi Mumbai, India), T. Lele (Vashi, Navi Mumbai, India), A. Leuppi-Taegtmeyer (Liestal, Switzerland), J. Leuppi (Liestal, Switzerland), P. Chhajed (Vashi, Navi Mumbai, India)
Clinical course of IPF Italian patients during 12-month of observation: results from the FIBRONET observational study V. Poletti (Forlì, Italy), C. Vancheri (Catania, Italy), C. Albera (Torino, Italy), S. Harari (Milano, Italy), A. Pesci (Monza, Italy), P. Rottoli (Siena, Italy), B. Campolo (Milano, Italy), D. Lorenzo (Milano, Italy), R. Barbara On Behalf Of Fibronet Study Group (Modena, Italy)
Real-life experience of familial fibrosis in a Belgian university A. Petit (Brussels, Belgium), C. Dahlqvist (Yvoir, Belgium), A. De Leener (Brussels, Belgium), C. Kannengiesser (Paris, France), R. Borie (Paris, France), A. Froidure (Brussels, Belgium)
PFBIO — a prospective longitudinal IPF cohort N. Hoyer (Hellerup, Denmark), T. Prior (Aarhus, Denmark), E. Bendstrup (Aarhus, Denmark), T. Wilcke (Hellerup, Denmark), S. Shaker (Hellerup, Denmark)
A registry of patients with idiopathic pulmonary fibrosis in Russia: 2-yr results and therapeutic modalities in real-life practice S. Chikina (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), A. Belevsky (Moscow, Russian Federation), A. Cherniak (Moscow, Russian Federation), N. Kravchenko (Moscow, Russian Federation)
Revised UIP/IPF diagnoses after the 2018 international guidelines: a 15-year Padova-Strasbourg experience F. Calabrese (Padova, Italy), F. Lunardi (Padova, Italy), E. Balestro (Padova, Italy), E. Cocconcelli (Padova, Italy), C. Giraudo (Padova, Italy), R. Polverosi (Padova, Italy), E. Faccioli (Padova, Italy), F. Rea (Padova, Italy), A. Fattori (Strasbourg, France), M. Chenard (Strasbourg, France), M. Ohana (Strasbourg, France), A. Labani (Strasbourg, France), R. Kessler (Strasbourg, France), S. Hirschi (Strasbourg, France)
Autoantibodies in patients with idiopathic pulmonary fibrosis D. Kalafatis (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), G. Ferrara (Stockholm, Sweden), M. Sköld (Stockholm, Sweden)
Clinical meaning of IPAF in a real-life cohort of IPF patients S. Puglisi (Forlì, Italy), S. Tomassetti (Forlì, Italy), M. Bosi (Forlì, Italy), C. Ravaglia (Forlì, Italy), A. Arcadu (Forlì, Italy), A. Caringella (Acquaviva delle Fonti, Italy), L. Bivona (Caltanisetta, Italy), M. Marchi (Forlì, Italy), A. Mendez (Vila Nova de Gaia, Portugal), F. Carrico (Guarda, Portugal), C. Gurioli (Forlì, Italy), L. Donati (Forlì, Italy), S. Piciucchi (Forlì, Italy), A. Dubini (Forlì, Italy), V. Poletti (Aarhus, Denmark)
Experience in PIBO in our center G. Gemma (barBarcelona, Spain), (Barcelona, Spain), I. De Mir Messa (Barcelona, Spain), L. Garriga Grimau (Barcelona, Spain), S. Gartner Tizzano (Barcelona, Spain), I. Iglesias Serrano (Barcelona, Spain), S. Rovira Amigo (Barcelona, Spain), A. Torrent Vernetta (Barcelona, Spain), A. Moreno Galdo (Barcelona, Spain)
Longitudinal observation of idiopathic pulmonary fibrosis (IPF) patients cohort from one center in Poland. K. Lewandowska (Warsaw, Poland), P. Radwan-Rohrenschef (Warsaw, Poland), M. Sobiecka (Warsaw, Poland), M. Bartosiewicz (Warsaw, Poland), I. Siemion-Szczesniak (Warsaw, Poland), S. Wesolowski (Warsaw, Poland), I. Bestry (Warsaw, Poland), A. Gladzka (Warsaw, Poland), D. Klatka (Warsaw, Poland), J. Kus (Warsaw, Poland)
Idiopathic Pulmonary Fibrosis: mortality trends in Chile L. Mendoza Inzunza (Santiago de Chile, Chile), G. Cavada (Santiago de Chile, Chile), P. Matus (Santiago de Chile, Chile), . Valdés (Santiago de Chile, Chile)
Unclassifiable interstitial lung disease: predictive factors of mortality and radiologic features D. Oliveira Reis (Vila Nova de Gaia, Portugal), P. Melo (Vila Nova de Gaia, Portugal), I. Marques (Vila Nova de Gaia, Portugal), A. Sanches (Vila Nova de Gaia, Portugal), C. Nogueira (Vila Nova de Gaia, Portugal), S. Campainha (Vila Nova de Gaia, Portugal), S. Neves (Vila Nova de Gaia, Portugal)
The utilization pattern of surgical lung biopsies (SLB) for the diagnosis of interstitial lung diseases (ILD) in Sri Lanka A. Rathnapala (Welisara, Sri Lanka), S. Wickramasinghe (Welisara, Sri Lanka), D. Tilakaratne (Welisara, Sri Lanka), H. Chreif (Oxford, United Kingdom), S. Palihawadana (Welisara, Sri Lanka), D. Handagala (Welisara, Sri Lanka), E. Perera (Welisara, Sri Lanka), S. Kularatne (Welisara, Sri Lanka), B. Gunasena (Welisara, Sri Lanka), R. Punchihewa (Welisara, Sri Lanka)
Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry. M. Vasakova (Prague, Czech Republic), M. Sterclova (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), K. Lawandowska (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hajkova (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Kramer (Petah Tikva, Israel), M. Studnicka (Salzburg, Austria), N. Stoeva (Sofia, Bulgaria), S. Littnerova (Brno, Czech Republic), K. Hejduk (Brno, Czech Republic), L. Dusek (Brno, Czech Republic)
Healthcare resource utilization and direct costs of interstitial lung disease management in Germany P. Maqhuzu (Munich, Germany), L. Schwarzkopf (Munich, Germany), M. Kreuter (Heidelberg, Germany)
Health-related quality of life development in IPF versus other ILD – the HILDA study B. Szentes (Neuherberg, Germany), P. Maqhuzu (Neuherberg, Germany), M. Kreuter (Heidelberg, Germany), T. Bahmer (Großhansdorf, Germany), M. Claussen (Großhansdorf, Germany), L. Schwarzkopf (Neuherberg, Germany)
DANILDA – The First Danish National Interstitial Lung Disease Registry E. Bendstrup (Aarhus, Denmark), A. Yde (Aarhus, Denmark), C. Hyldgaard (Silkeborg, Denmark), S. Shaker (Copenhagen, Denmark), J. Davidsen (Odense, Denmark)
SURVIVAL OF THE IDIOPATHIC PULMONARY FIBROSIS (IPF) IN SPAIN. NATIONAL SEPAR REGISTRY S. Jaimes Diaz (Valencia, Spain), J. Rodríguez Portal (Sevilla, Spain), E. Fernández Fabrellas (Valencia, Spain), M. Aburto Barrenetxea (Vizcaya, Spain), C. Valenzuela Valenzuela (Mdrid, Spain), L. Planas Cerezales (Barcelona, Spain), R. García Sevila (Alicante, Spain), E. Bollo De Miguel (León, Spain), S. Herrera Lara (Vslencia, Spain), J. González Ruiz (Salamanca, Spain), R. Sánchez Simón (Albacete, Spain)
Treatment and survival diversities in different forms of ILD in Germany - EXCITING registry M. Kreuter (Heidelberg, Germany), H. Kabitz (Konstanz, Germany), L. Hagmeyer (Solingen, Germany), P. Hammerl (Immenhausen, Germany), A. Esselmann (Warendorf, Germany), C. Wiederhold (Fulda, Germany), D. Skowasch (Bonn, Germany), C. Stolpe (Ibbenbüren, Germany), M. Joest (Bonn, Germany), S. Veitshans (Böblingen, Germany), P. Maqhuzu (Neuherberg, Germany), L. Schwarzkopf (Munich, Germany), A. Hellmann (Augsburg, Germany), M. Pfeifer (Donaustauf, Germany), J. Behr (Munich, Germany), D. Kauschka (Essen, Germany), A. Günther (Giessen, Germany), F. Herth (Heidelberg, Germany), P. Markart (Fulda, Germany)